Literature DB >> 30106098

Dexmedetomidine pretreatment inhibits cerebral ischemia/reperfusion‑induced neuroinflammation via activation of AMPK.

Zhenhong Wang1, Wei Zhou1, Haiping Dong1, Xiaoxiao Ma1, Zhenzhou He1.   

Abstract

Focal ischemia/reperfusion (I/R) injury induced cerebral inflammation, aggravates brain damage. The aim of the present study was to investigate the protective mechanisms of dexmedetomidine (DEX) on I/R brain injury in rats. Sprague‑Dawley rats were divided to seven experimental groups (18 rats/group): Sham surgery; middle cerebral artery occlusion (MCAO) surgery (90 min); DEX10 [10 µg/kg intraperitoneal (i.p.) injection 30 min prior to MCAO]; DEX50 (50 µg/kg i.p. 30 min prior to MCAO); DEX100 (100 µg/kg i.p. 30 min prior to MCAO); DEX50+Yohimbine [YOH; 5 mg/kg 10 min prior to DEX (50 µg/kg i.p.) administration and MCAO] and YOH (5 mg/kg 40 min prior to MCAO). At 24 h post‑MCAO surgery, neurological deficit was examined by staining damaged brain tissues with 2,3,5‑triphenyltetrazolium chloride. Neuronal apoptosis in the cerebral cortex was histologically assessed by terminal deoxynucleotidyl‑transferase‑mediated dUTP nick end labeling staining, and the expression levels of phosphorylated (p)‑AMP‑activated protein kinase (AMPK; Thr172) was detected by western blotting. In addition, the expression levels of tumor necrosis factor (TNF)‑α and interleukin (IL)‑1β were assessed by ELISA. At days 1, 2 and 5 following I/R, motor functions were assessed by an observer blinded to the study. The brain infarct size, neurological deficit scores, number of apoptotic neurons, expression levels of pro‑inflammatory cytokines TNF‑α and IL‑1β were increased following MCAO, whereas the motor function scores were reduced. Pretreatment with DEX prior to MCAO can reverse the effects induced by I/R. Compared with rats in the Sham group, the expression levels of p‑AMPK were mildly increased in the MCAO group and highly increased in the three DEX‑treatment groups. Pretreatment with YOH reversed the above effects of DEX and produced a similar level of cerebral I/R injury. The results demonstrated that precondition with DEX exhibited anti‑inflammatory effects on brain ischemic injury mediated by AMPK signal pathway.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30106098     DOI: 10.3892/mmr.2018.9349

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

1.  Perisciatic Nerve Dexmedetomidine Alleviates Spinal Oxidative Stress and Improves Peripheral Mitochondrial Dynamic Equilibrium in a Neuropathic Pain Mouse Model in an AMPK-Dependent Manner.

Authors:  Yang Mu; Yang Mei; Yaohua Chen; Yuping Li; Dan Zhu; Jian Cui; Lehua Yu
Journal:  Dis Markers       Date:  2022-06-20       Impact factor: 3.464

2.  Dexmedetomidine Enhances Autophagy via α2-AR/AMPK/mTOR Pathway to Inhibit the Activation of NLRP3 Inflammasome and Subsequently Alleviates Lipopolysaccharide-Induced Acute Kidney Injury.

Authors:  Tianyuan Yang; Xiujing Feng; Yuan Zhao; Haiyang Zhang; Hailin Cui; Mian Wei; Haotian Yang; Honggang Fan
Journal:  Front Pharmacol       Date:  2020-06-24       Impact factor: 5.810

Review 3.  Aloperine: A Potent Modulator of Crucial Biological Mechanisms in Multiple Diseases.

Authors:  Muhammad Tahir; Sakhawat Ali; Wenting Zhang; Boqiang Lv; Wenge Qiu; Juan Wang
Journal:  Biomedicines       Date:  2022-04-15

4.  Perioperative Dexmedetomidine attenuates brain ischemia reperfusion injury possibly via up-regulation of astrocyte Connexin 43.

Authors:  Xiaoyang Zheng; Xiaoying Cai; Fang Ye; Ying Li; Qin Wang; Zhiyi Zuo; Wenqi Huang; Zhongxing Wang
Journal:  BMC Anesthesiol       Date:  2020-12-07       Impact factor: 2.217

Review 5.  Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease.

Authors:  Rishika Dhapola; Subhendu Shekhar Hota; Phulen Sarma; Anusuya Bhattacharyya; Bikash Medhi; Dibbanti HariKrishna Reddy
Journal:  Inflammopharmacology       Date:  2021-11-23       Impact factor: 4.473

6.  Circular RNA cerebellar degeneration-related protein 1 antisense RNA (Circ-CDR1as) downregulation induced by dexmedetomidine treatment protects hippocampal neurons against hypoxia/reoxygenation injury through the microRNA-28-3p (miR-28-3p)/tumor necrosis factor receptor-associated factor-3 (TRAF3) axis.

Authors:  Junhua Wang; Ying Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Dexmedetomidine Can Enhance PINK1/Parkin-Mediated Mitophagy in MPTP-Induced PD Mice Model by Activating AMPK.

Authors:  Cheng Chen; Yaohua Chen; Tingting Liu; Dan Song; Di Ma; Oumei Cheng
Journal:  Oxid Med Cell Longev       Date:  2022-04-12       Impact factor: 7.310

8.  Dexmedetomidine pretreatment alleviates cerebral ischemia/reperfusion injury by inhibiting neuroinflammation through the JAK2/STAT3 pathway.

Authors:  Huan Liu; Jianli Li; Li Jiang; Jinhua He; Huanhuan Zhang; Keyan Wang
Journal:  Braz J Med Biol Res       Date:  2022-07-13       Impact factor: 2.904

Review 9.  The neuroprotective effect of dexmedetomidine and its mechanism.

Authors:  Yijun Hu; Hong Zhou; Huanxin Zhang; Yunlong Sui; Zhen Zhang; Yuntao Zou; Kunquan Li; Yunyi Zhao; Jiangbo Xie; Lunzhong Zhang
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

10.  Dexmedetomidine Attenuates Myocardial Ischemia-Reperfusion Injury in Diabetes Mellitus by Inhibiting Endoplasmic Reticulum Stress.

Authors:  Jinjie Li; Ying Zhao; Nan Zhou; Longyun Li; Kai Li
Journal:  J Diabetes Res       Date:  2019-11-30       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.